Physician

Bryan Kyle Rutledge, M.D.

According to 2025 Medicare claims, Bryan Rutledge, M.D. (NPI: 1053307272) practices ophthalmology in the Syracuse, NY market, with the plurality of this provider's patient population coming from Onondaga, NY. This provider's primary affiliated billing organization is RETINA-VITREOUS SURGEONS OF CENTRAL NEW YORK, PC (NPI: 1124012737; TIN: 16-0993668) and primary practice location at 13088-6655.

Rutledge's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 615 traditional Medicare patients, billed 17,773 HCPCS/CPT codes, and received $1,755,453 in Medicare payments. The top billing code was J0178 (Injection, aflibercept, 1 mg). Part D data shows 215 prescription claims across 80 beneficiaries totaling $9,141 in drug costs, led by Prednisolone Acetate (Prednisolone Acetate). Open Payments data shows 5 records totaling $128. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has declined steadily, from $2,642,974 to $1,755,453. Concurrently, Part D prescription costs have changed little. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Part B Carrier Billing Trend. X-axis: year 2015-2024. Y-axis: Medicare payment, unit: USD. Field: Tot_Mdcr_Pymt_Amt. Source: Medicare Physician & Other Practitioners by Provider.0$1.4M$2.9M2015 Medicare payment: $2,642,974 (USD; Tot_Mdcr_Pymt_Amt)2016 Medicare payment: $2,882,794 (USD; Tot_Mdcr_Pymt_Amt)2017 Medicare payment: $2,731,291 (USD; Tot_Mdcr_Pymt_Amt)2018 Medicare payment: $2,557,514 (USD; Tot_Mdcr_Pymt_Amt)2019 Medicare payment: $2,630,382 (USD; Tot_Mdcr_Pymt_Amt)2020 Medicare payment: $2,735,170 (USD; Tot_Mdcr_Pymt_Amt)2021 Medicare payment: $2,588,008 (USD; Tot_Mdcr_Pymt_Amt)2022 Medicare payment: $2,260,517 (USD; Tot_Mdcr_Pymt_Amt)2023 Medicare payment: $1,742,120 (USD; Tot_Mdcr_Pymt_Amt)2024 Medicare payment: $1,755,453 (USD; Tot_Mdcr_Pymt_Amt)2015201620172018201920202021202220232024
YearPatientsClm LinesPayment
201578811,298$2,642,974
20168199,905$2,882,794
20178439,961$2,731,291
20188419,026$2,557,514
20198469,845$2,630,382
20207478,996$2,735,170
20217318,564$2,588,008
20226697,817$2,260,517
202345610,385$1,742,120
202461517,773$1,755,453

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Part D Events Trend. X-axis: year 2015-2024. Y-axis: Drug cost, unit: USD. Field: Tot_Drug_Cst. Source: Medicare Part D Prescribers by Provider.0$6.5K$13K2015 Drug cost: $13,039 (USD; Tot_Drug_Cst)2016 Drug cost: $9,952 (USD; Tot_Drug_Cst)2017 Drug cost: $12,018 (USD; Tot_Drug_Cst)2018 Drug cost: $11,296 (USD; Tot_Drug_Cst)2019 Drug cost: $11,190 (USD; Tot_Drug_Cst)2020 Drug cost: $12,522 (USD; Tot_Drug_Cst)2021 Drug cost: $9,079 (USD; Tot_Drug_Cst)2022 Drug cost: $9,355 (USD; Tot_Drug_Cst)2023 Drug cost: $9,833 (USD; Tot_Drug_Cst)2024 Drug cost: $9,141 (USD; Tot_Drug_Cst)2015201620172018201920202021202220232024
YearPatientsClaimsDrug Cost
201593242$13,039
201676200$9,952
201780218$12,018
2018105275$11,296
2019102288$11,190
202095250$12,522
2021108238$9,079
202274210$9,355
202364134$9,833
202480215$9,141

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

CodeDescriptionPatientsClm LinesTotal Payment
J0178Injection, aflibercept, 1 mg1991,664$640
99214Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more172181$92
92014Established patient complete exam of visual system195210$91
67028Injection of drug into eye2801,098$88
92134Imaging of retina5231,474$30

Top 5 Part D drugs in 2024

By total drug costs.

DrugGenericClaimsTotal Day SupplyTotal Drug Cost
Prednisolone AcetatePrednisolone Acetate842,924$3,452
Ketorolac TromethamineKetorolac Tromethamine451,313$796
TobramycinTobramycin35892$190

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

CategoryDefinitionRecordsTotal Reported AmountTop Related Entity
General PaymentsReported payment or transfer-of-value amount.5$128Regeneron Healthcare Solutions, Inc.
Research PaymentsReported research-related payment or transfer-of-value amount.0$0N/R
Ownership / Investment InterestsReported value of ownership or investment interests.0$0N/R

FAQ

What Medicare data is available for Bryan Kyle Rutledge, M.D.?

Tedicare shows public-source Medicare data for Bryan Kyle Rutledge, M.D. (NPI 1053307272), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Bryan Kyle Rutledge, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Bryan Kyle Rutledge, M.D.?

Bryan Kyle Rutledge, M.D. is linked to RETINA-VITREOUS SURGEONS OF CENTRAL NEW YORK, PC (billing NPI 1124012737) in the available physician profile data.

Does Bryan Kyle Rutledge, M.D. have Open Payments data?

Bryan Kyle Rutledge, M.D. has 5 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.